HK1245256B - Pyridyl and fused pyridyl triadimefon derivatives - Google Patents
Pyridyl and fused pyridyl triadimefon derivatives Download PDFInfo
- Publication number
- HK1245256B HK1245256B HK18104553.1A HK18104553A HK1245256B HK 1245256 B HK1245256 B HK 1245256B HK 18104553 A HK18104553 A HK 18104553A HK 1245256 B HK1245256 B HK 1245256B
- Authority
- HK
- Hong Kong
- Prior art keywords
- mmol
- compound
- pharmaceutically acceptable
- tautomer
- hydrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776445P | 2013-03-11 | 2013-03-11 | |
| US201361776445P | 2013-03-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1245256A1 HK1245256A1 (en) | 2018-08-24 |
| HK1245256B true HK1245256B (en) | 2019-09-27 |
Family
ID=50543655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18104553.1A HK1245256B (en) | 2013-03-11 | 2018-04-06 | Pyridyl and fused pyridyl triadimefon derivatives |
Country Status (43)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| KR20220027271A (ko) | 2014-02-21 | 2022-03-07 | 프린시피아 바이오파마, 인코퍼레이티드 | Btk 억제제의 염 및 고체 형태 |
| CN104447530A (zh) * | 2014-12-11 | 2015-03-25 | 苏州欧凯医药技术有限公司 | 4-甲基-2,6-二羧基吡啶的制备方法 |
| CA2970723C (en) | 2014-12-18 | 2023-09-05 | Principia Biopharma Inc. | Treatment of pemphigus |
| MA42242A (fr) | 2015-06-24 | 2018-05-02 | Principia Biopharma Inc | Inhibiteurs de la tyrosine kinase |
| UY37046A (es) | 2015-12-24 | 2017-07-31 | Takeda Pharmaceuticals Co | Cocristal, método de produccion del mismo,y medicamento que contiene dicho cocristal |
| WO2017122175A1 (en) * | 2016-01-13 | 2017-07-20 | Acerta Pharma B.V. | Therapeutic combinations of an antifolate and a btk inhibitor |
| DK3436447T3 (da) * | 2016-03-31 | 2021-09-13 | Takeda Pharmaceuticals Co | Isoquinolinyl-triazolon-komplekser |
| WO2018005849A1 (en) | 2016-06-29 | 2018-01-04 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| BR112021000964A2 (pt) | 2018-07-25 | 2021-04-20 | Novartis Ag | inibidores do inflamassoma de nlrp3 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| KR102459858B1 (ko) * | 2019-04-02 | 2022-10-27 | 연세대학교 산학협력단 | 신규 화합물 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 조성물 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| TWI877239B (zh) | 2019-10-14 | 2025-03-21 | 美商普林斯匹亞生物製藥公司 | 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| BR112022014149A2 (pt) | 2020-01-22 | 2022-09-27 | Principia Biopharma Inc | Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)-1h-pirazolo[3,4-d]pirimidina-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrila |
| AU2021325431B2 (en) | 2020-08-14 | 2024-01-18 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| WO2025116652A1 (ko) * | 2023-11-30 | 2025-06-05 | 주식회사 지엔티파마 | 자가면역 질환 치료용 조성물 및 방법 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| US5733849A (en) * | 1996-03-15 | 1998-03-31 | Rohm And Haas Company | Halopyridyl triazolinone herbicides and herbicidal use thereof |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| ATE269295T1 (de) | 1998-04-17 | 2004-07-15 | Parker Hughes Inst | Btk inhibitoren und verfahren zur identifizierung und verwendung |
| ATE346064T1 (de) * | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| DK1347971T3 (da) | 2000-12-21 | 2006-05-15 | Bristol Myers Squibb Co | Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien |
| US7572809B2 (en) * | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| CN101421269A (zh) | 2006-01-13 | 2009-04-29 | 环状药物公司 | 酪氨酸激酶抑制剂及其用途 |
| US8053456B2 (en) * | 2006-05-25 | 2011-11-08 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate Hsp90 activity |
| JP2009541252A (ja) | 2006-06-20 | 2009-11-26 | エフ．ホフマン−ラ ロシュ アーゲー | テトラリン及びインダン誘導体ならびにそれらの使用 |
| AR063946A1 (es) | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| PT2201840E (pt) | 2006-09-22 | 2012-02-14 | Pharmacyclics Inc | Inibidores da tirosina quinase de bruton |
| EA017865B1 (ru) | 2007-03-28 | 2013-03-29 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| ES2462642T3 (es) | 2007-12-14 | 2014-05-26 | F. Hoffmann-La Roche Ag | Nuevos derivados de imidazo[1,2-a]piridina e imidazo[1,2-b]piridazina |
| CA2710462C (en) | 2008-02-05 | 2015-11-24 | F. Hoffmann-La Roche Ag | Pyridinones and pyridazinones |
| CN103709148B (zh) | 2008-06-24 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 取代的吡啶-2-酮和哒嗪-3-酮 |
| JP5490789B2 (ja) | 2008-07-02 | 2014-05-14 | エフ．ホフマン−ラ ロシュ アーゲー | キナーゼ阻害剤としての新規なフェニルピラジノン |
| ES2552681T3 (es) | 2008-07-15 | 2015-12-01 | F. Hoffmann-La Roche Ag | Nuevas fenil-imidazopiridinas y piridazinas |
| WO2010056875A1 (en) | 2008-11-12 | 2010-05-20 | Cgi Pharmaceuticals, Inc. | Pyridazinones and their use as btk inhibitors |
| WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
| WO2010068810A2 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| US8497265B2 (en) | 2010-05-13 | 2013-07-30 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
| MX367623B (es) | 2010-10-20 | 2019-08-29 | Gruenenthal Gmbh | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. |
| JP2013544321A (ja) | 2010-11-10 | 2013-12-12 | エスティーシー． ユーエヌエム | ゼロ原子価金属粒子用エアロゾル還元／膨張合成（ａ−ｒｅｓ） |
| JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
-
2014
- 2014-03-05 JO JOP/2014/0070A patent/JO3377B1/ar active
- 2014-03-10 PL PL14719130T patent/PL2970202T3/pl unknown
- 2014-03-10 ES ES14719130.8T patent/ES2624439T3/es active Active
- 2014-03-10 EP EP17152008.3A patent/EP3235814B1/en active Active
- 2014-03-10 MX MX2015011533A patent/MX364527B/es active IP Right Grant
- 2014-03-10 CA CA2899948A patent/CA2899948C/en active Active
- 2014-03-10 SI SI201430203A patent/SI2970202T1/sl unknown
- 2014-03-10 TW TW103108214A patent/TWI637950B/zh active
- 2014-03-10 SM SM20170218T patent/SMT201700218T1/it unknown
- 2014-03-10 ES ES17152008T patent/ES2714166T3/es active Active
- 2014-03-10 DK DK14719130.8T patent/DK2970202T3/en active
- 2014-03-10 KR KR1020157028600A patent/KR102300612B1/ko active Active
- 2014-03-10 ME MEP-2017-98A patent/ME02693B/me unknown
- 2014-03-10 BR BR112015020264-0A patent/BR112015020264B1/pt active IP Right Grant
- 2014-03-10 PT PT147191308T patent/PT2970202T/pt unknown
- 2014-03-10 MA MA38391A patent/MA38391B1/fr unknown
- 2014-03-10 UA UAA201507597A patent/UA114944C2/uk unknown
- 2014-03-10 LT LTEP14719130.8T patent/LT2970202T/lt unknown
- 2014-03-10 JP JP2016501072A patent/JP6271700B2/ja active Active
- 2014-03-10 EA EA201591686A patent/EA028584B1/ru unknown
- 2014-03-10 MY MYPI2015703082A patent/MY183927A/en unknown
- 2014-03-10 EP EP14719130.8A patent/EP2970202B1/en active Active
- 2014-03-10 RS RS20170414A patent/RS55879B1/sr unknown
- 2014-03-10 HR HRP20170622TT patent/HRP20170622T1/hr unknown
- 2014-03-10 US US14/203,366 patent/US9402841B2/en active Active
- 2014-03-10 UY UY0001035376A patent/UY35376A/es not_active Application Discontinuation
- 2014-03-10 AP AP2015008646A patent/AP2015008646A0/xx unknown
- 2014-03-10 PE PE2015001905A patent/PE20151889A1/es active IP Right Grant
- 2014-03-10 WO PCT/US2014/022801 patent/WO2014164558A1/en not_active Ceased
- 2014-03-10 SG SG11201506112QA patent/SG11201506112QA/en unknown
- 2014-03-10 AU AU2014249248A patent/AU2014249248B2/en active Active
- 2014-03-10 CN CN201480012902.5A patent/CN105121427B/zh active Active
- 2014-03-10 GE GEAP201413953A patent/GEP201706778B/en unknown
- 2014-03-10 AR ARP140100805A patent/AR095198A1/es active IP Right Grant
- 2014-03-10 HU HUE14719130A patent/HUE032720T2/en unknown
-
2015
- 2015-08-04 IL IL240353A patent/IL240353B/en active IP Right Grant
- 2015-08-06 DO DO2015000184A patent/DOP2015000184A/es unknown
- 2015-08-11 TN TN2015000342A patent/TN2015000342A1/en unknown
- 2015-08-19 ZA ZA2015/05996A patent/ZA201505996B/en unknown
- 2015-08-24 CL CL2015002370A patent/CL2015002370A1/es unknown
- 2015-09-10 PH PH12015502046A patent/PH12015502046B1/en unknown
- 2015-09-10 CR CR20150470A patent/CR20150470A/es unknown
- 2015-10-08 EC ECIEPI201542779A patent/ECSP15042779A/es unknown
-
2016
- 2016-06-29 US US15/197,051 patent/US9801872B2/en active Active
-
2017
- 2017-04-25 CY CY20171100458T patent/CY1119356T1/el unknown
- 2017-09-27 US US15/717,624 patent/US10307414B2/en active Active
- 2017-12-27 JP JP2017252294A patent/JP6462842B2/ja active Active
-
2018
- 2018-04-06 HK HK18104553.1A patent/HK1245256B/en unknown
-
2019
- 2019-04-03 US US16/374,430 patent/US20190224190A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3235814B1 (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| HK1245256A1 (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| EP3489236B1 (en) | Process for the preparation of fused heteroaromatic pyrrolidinones | |
| US9365566B2 (en) | Cinnoline derivatives | |
| EP2723739B1 (en) | Substituted 6-aza-isoindolin-1-one derivatives | |
| WO2022066917A1 (en) | 3-(6-aminopyridin-3-yl)benzamide derivatives as ripk2 inhibitors | |
| WO2020198053A1 (en) | 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases | |
| HK1220183B (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| HK40051882A (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
| NZ710852B2 (en) | Pyridinyl and fused pyridinyl triazolone derivatives |